Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;3(1):43-52.
doi: 10.1177/1756285609349521.

Progress in the management of paraneoplastic neurological disorders

Hamid Sadeghian  1 , Steven Vernino
Affiliations

Progress in the management of paraneoplastic neurological disorders

Hamid Sadeghian et al. Ther Adv Neurol Disord. 2010 Jan.

Abstract

Paraneoplastic neurological disorders (PNDs) are a rare and diverse group of neurological conditions that can involve any part of the nervous system. Diagnosis is facilitated by finding well-recognized autoantibodies directed against neural antigens in the sera and the cerebrospinal fluid. Identifying and eliminating the underlying malignancy is the mainstay of treatment. Immunomodulatory treatment is gaining more acceptance especially, where a malignancy could not be identified, oncology treatment is completed, or along with cancer treatment. Literature review shows only a handful of systematic prospective case series. Multicenter, prospective controlled clinical trials are needed for future therapeutic advances.

Keywords: cyclophosphamide; intravenous immunoglobulin; limbic encephalitis; neuroimmunology; plasma exchange.

PubMed Disclaimer

References

    1. Albert M.L., Austin L.M., Darnell R.B. (2000) Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 47: 9–17 - PubMed
    1. Albert M.L., Darnell J.C., Bender A., Francisco L.M., Bhardwaj N., Darnell R.B. (1998) Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nature Med 4: 1321–1324 - PubMed
    1. Armstrong M.B., Robertson P.L., Castle V.P. (2005) Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis. Pediatric Neurol 33: 365–367 - PubMed
    1. Basu S., Alavi A. (2008) Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 10: 131–137 - PubMed
    1. Batchelor T.T., Platten M., Hochberg F.H. (1998) Immunoadsorption therapy for paraneoplastic syndromes. J Neuro-Oncol 40: 131–136 - PubMed

LinkOut - more resources